Patients must not have malabsorption, swallowing difficulty, or other conditions that would interfere with the ingestion or absorption of dabrafenib or trametinib
Difficulty with swallowing or an active malabsorption syndrome.
Difficulty swallowing capsules or requirement for a feeding tube.
Known history of difficulty swallowing, malabsorption or other conditions that may reduce absorption of the product.
Difficulty swallowing, malabsorption, known active partial or complete bowel obstruction, or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of capecitabine
Patient is capable of swallowing pills whole
Patient must be capable of swallowing the ruxolitinib capsules (tablets)
Patient is capable of swallowing pills whole
Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
Previous history of difficulty swallowing capsules.
Be capable of swallowing study agents whole as a tablet
Pre-treatment swallowing evaluation by speech and swallowing therapist, to included a modified barium swallow showing no significant impairment with swallowing oral medications
History of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the IMP, use of percutaneous endoscopic gastrostomy (PEG) tubes
History of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the IMP
Difficulty swallowing or malabsorption
History of significant difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the tested product
Relapsed/refractory MCL: Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty
Newly diagnosed MCL: Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty
Difficulty with swallowing, or an active malabsorption syndrome.
Difficulty with swallowing or an active malabsorption syndrome
Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty.
History of difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the investigational product
Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
Difficulty swallowing capsules.
All subjects must be capable of swallowing multiple capsules
Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty
Patient is capable of swallowing study drug capsules whole.
Willing and able to participate in all study related procedures and therapy including swallowing capsules without difficulty
Capable of swallowing tablets
Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty.
Patient is capable of swallowing.
Known gastrointestinal disease or condition that affects the absorption of ASN001, or difficulty swallowing large capsules.
Willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty
Subject has difficulty swallowing large pills.
The subject has difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the trial drug. Subjects requiring total parenteral nutrition are to be excluded.
Has difficulty swallowing medications, or known history of malabsorption syndrome;
Capable of swallowing intact study medication capsules
Active difficulty swallowing, malabsorption or other chronic gastrointestinal disease or conditions (including pancreas deficiency requiring Creon therapy) that may hamper compliance and/or absorption of M3541
